Related Experiment Video
Updated: Jan 20, 2026
Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
Exacerbation Risk by Chronic Proton Pump Inhibitor Use in Obstructive Lung Diseases
Valerie Dehondt1, Frauke Van Vaerenbergh1, Katia Verhamme2
1Pharmaceutical Care Unit, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Background:
Previous studies have shown inconsistent results regarding the use of proton pump inhibitors (PPIs) and the risk on exacerbations in patients with chronic obstructive airway diseases (COADs).
Research Question:
Is long-term PPI use associated with exacerbation risk?
Study Design And Methods:
Using Belgian nationwide claims-based data of adult patients receiving long-term medication for COADs between 2017 and 2022, we investigated the association between PPI use and exacerbation risk using multivariable Cox models. Based on defined daily doses (DDDs) dispensed during the prior year, dose-dependent associations were assessed by inverse probability of treatment weighted Cox regression models.
Results:
Among 932,135 included patients with COADs, 416,087 patients (44.6%) were PPI users, of whom 57,540 patients (13.8%) received 1-28 DDDs of PPIs, 128,017 patients (30.8%) received 29-180 DDDs, 127,981 patients (30.8%) received 181-365 DDDs, and 102,549 patients (24.6%) received > 365 DDDs in the previous year. Beyond age, sex, smoking, socioeconomic status, exacerbation history, short-acting bronchodilator use, frailty, and comorbidities, PPI use was associated with an increased risk of exacerbations (adjusted hazard ratio [HR], 1.18 [95% CI, 1.17-1.19]). Moreover, compared with patients who did not use PPIs, the risk of exacerbations increased with cumulative DDDs (≤ 28 DDDs: HR, 1.09 [95% CI, 1.07-1.10]; ≤ 180 DDDs: HR, 1.15 [95% CI, 1.14-1.16]; ≤ 365 DDDs: HR, 1.19 [95% CI, 1.18-1.20]; and > 365 DDDs: HR, 1.25 [95% CI, 1.23-1.26]). Sensitivity analyses indicated that the association with exacerbation risk was most pronounced in patients younger than 50 years, who were not frail, and with theoretically increased PPI plasma concentrations, and was not significant when used short-term in patients with gastroesophageal reflux disease.
Interpretation:
Cumulative PPI use in patients with obstructive lung diseases was associated with an increase in exacerbation risk. This highlights the need to consider PPI use carefully in clinical respiratory practice.
Related Concept Videos
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
04:53Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
08:17Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
02:34Auricular Acupressure as an Adjuvant Treatment for Wheezing in Stable Chronic Obstructive Pulmonary Disease
04:03Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians